These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 34135013)
1. Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes. Kahkoska AR; Abrahamsen TJ; Alexander GC; Bennett TD; Chute CG; Haendel MA; Klein KR; Mehta H; Miller JD; Moffitt RA; Stürmer T; Kvist K; Buse JB; Diabetes Care; 2021 Jul; 44(7):1564-1572. PubMed ID: 34135013 [TBL] [Abstract][Full Text] [Related]
2. Association of Premorbid GLP-1RA and SGLT-2i Prescription Alone and in Combination with COVID-19 Severity. Klein KR; Abrahamsen TJ; Kahkoska AR; Alexander GC; Chute CG; Haendel M; Hong SS; Mehta H; Moffitt R; Stürmer T; Kvist K; Buse JB; Diabetes Ther; 2024 May; 15(5):1169-1186. PubMed ID: 38536629 [TBL] [Abstract][Full Text] [Related]
3. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes. Richardson TL; Halvorson AE; Hackstadt AJ; Hung AM; Greevy R; Grijalva CG; Elasy TA; Roumie CL Ann Intern Med; 2023 Jun; 176(6):751-760. PubMed ID: 37155984 [TBL] [Abstract][Full Text] [Related]
4. Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes. Essien UR; Singh B; Swabe G; Johnson AE; Eberly LA; Wadhera RK; Breathett K; Vaduganathan M; Magnani JW JAMA Netw Open; 2023 Jun; 6(6):e2316290. PubMed ID: 37261826 [TBL] [Abstract][Full Text] [Related]
5. Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care. O'Hara DV; Janse RJ; Fu EL; Jardine MJ; Carrero JJ Diabetes Res Clin Pract; 2024 Jul; 213():111745. PubMed ID: 38876274 [TBL] [Abstract][Full Text] [Related]
6. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074 [TBL] [Abstract][Full Text] [Related]
7. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System. Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725 [TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice. Fu EL; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero JJ Int J Cardiol; 2022 Apr; 352():172-179. PubMed ID: 35074492 [TBL] [Abstract][Full Text] [Related]
10. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis. Sabouret P; Bocchino PP; Angelini F; D'Ascenzo F; Galati G; Fysekidis M; DE Ferrari GM; Fischman DL; Bhatt DL; Biondi-Zoccai G Minerva Cardiol Angiol; 2023 Apr; 71(2):199-207. PubMed ID: 35195376 [TBL] [Abstract][Full Text] [Related]
11. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database. Eleftheriadou A; Riley D; Zhao SS; Austin P; Hernández G; Lip GYH; Jackson TL; Wilding JPH; Alam U Diabetologia; 2024 Jul; 67(7):1271-1282. PubMed ID: 38584180 [TBL] [Abstract][Full Text] [Related]
12. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118 [TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes. Varshney N; Billups SJ; Saseen JJ; Fixen CW Ther Adv Drug Saf; 2021; 12():2042098621997703. PubMed ID: 33854754 [TBL] [Abstract][Full Text] [Related]
14. Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes. Wei J; Choi HK; Dalbeth N; Li X; Li C; Zeng C; Lei G; Zhang Y JAMA Netw Open; 2023 Aug; 6(8):e2330885. PubMed ID: 37624597 [TBL] [Abstract][Full Text] [Related]